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Summary 
Background - Up to 40% of patients with metastatic melanoma (MM) develop brain metastases. Radiotherapy (RT) 
may potentiate the effects of immunotherapy (IO), even on distant sites (abscopal effect).  
Material and Methods - We retrospectively analyzed all our MM patients treated with IO within 6 months before/after 
brain RT between 2012 and 2016. Progression free (PFS) and overall survival (OS) were estimated with Kaplan-
Meier method and compared with controls treated with IO during the same period. 
Results - Thirty-six cases and 25 controls were identified. Among cases, 23 patients received an anti-CTLA4, 13 an 
anti-PD1. Eighteen cases were treated with stereotactic RT (SBRT), 18 with whole-brain RT (WBRT). Median PFS 
from the beginning of RT was 4 months in first line and 2 months in second line. A third of the cases progressed at 
first evaluation after RT. Median OS from the beginning of RT was 7 months in first line and 4 months in second 
line. Median PFS and OS of each treatment line showed a trend towards inferiority as compared to those of controls.  
Conclusion - Synergistim RT-IO was not observed in our case series. No cases of abscopal effect were seen and most 
patients underwent early systemic progression after RT.  
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Introduction 
Brain metastases are common in metastatic melanoma (MM), as 10-40% of patients develop intracranial progression 
during their disease history. Complications of brain lesions (e.g. bleeding, stroke, epilepsy) are the direct cause of 
death in most of these cases. On the other hand, prognosis of melanoma patients with brain metastases is poor, with 
median survival ranging from 4 to 10 months in different studies [1, 2]. Significant therapeutic advances have been 
seen in the field of MM in recent years. The advent of BRAF inhibitors, immune checkpoint inhibitors (ICIs) and 
their combination/sequence has revolutionized clinical practice, leading to a significant survival prolongation in 
comparison with old cytotoxic strategies [3-5]. Recently, pre-clinical and limited clinical evidences have supported 
the existence of a synergistic effect between brain radiotherapy (RT) and IO in MM [6-8]. A potential rationale could 
lie in the radiation-induced damage to the blood-brain barrier, leading to a better drug penetration in the central 
nervous system (CNS). More plausibly, RT could unmask cancer antigens, increasing the activity of drug-stimulated 
immune cells on distant localizations [9, 10]. This hypothesis may explain the so-called abscopal effect, that is the 
evidence of disease response at non-irradiated sites during RT in patients with systemic malignancies. Abscopal 
effect can be observed in hematological tumors, but some cases have been described also in solid cancers including 
MM [11-13]. Given the contradictory evidences regarding this topic, we aimed to investigate the potential interaction 
between brain RT and IO in a single Institution cohort of patients with MM. 
Methods 
 
 
We identified a cohort of patients with MM treated with brain RT and IO outside clinical trials at our Institution 
between 2012 and 2016, and another cohort of controls treated with IO but not brain RT in the same setting and time 
frame. Data about clinical features, disease characteristics, previous treatments (surgery, systemic therapies and RT), 
disease response and outcome were retrospectively collected from Institutional database. Descriptive statistics were 
used to report clinical variables. Admitted IO included either anti-CTLA4 (ipilimumab 3 mg/kg i.v. d1 q21), or anti-
PD1 (nivolumab 3 mg/kg i.v. d1 q14, pembrolizumab 2 mg/kg i.v. d1 q21). We considered as cases patients treated 
with external beam photon RT within 6 months since the beginning of IO, provided that no other oncologic therapies 
had been prescribed meanwhile. Stereotactic radiotherapy (SBRT) was administered as single fraction at a dose of 
20-24 Gy. Whole-brain radiotherapy (WBRT) was administered as 10 fractions at a dose of 3 Gy each, up to a total of 
30 Gy. Periodic evaluation of extra-cranial disease was performed with computed tomography (CT) and/or positron 
emission tomography (PET), at physician’s discretion. CNS lesions were evaluated with magnetic resonance (MRI), 
or with CT scan in patients presenting contraindications to MRI. Radiologic evaluations were performed every 8-12 
weeks, unless clinically indicated. Disease assessment was based on Response Evaluation Criteria for Solid Tumors 
(RECIST) v1.1 [14]. All patients signed an informed consent expressing agreement to the use of clinical data for 
research purposes at some time of their disease history. Progression-free and overall survival (PFS and OS, 
respectively) were estimated with Kaplan-Meier method. In particular, survival from RT, which was the primary 
objective of the analysis, was measured from the first day of RT to death or to data censoring. Comparisons between 
survival curves were performed with log-rank test. Chi squared or Fisher’s exact tests were used to assess differences 
between categorical data, Mann-Whitney U test was applied for continuous variables. All analyses were two-sided 
and statistical significance threshold was set at 0.05. Statistical analyses were performed with SAS (version 9.4, SAS 
Institute, Cary, NC, USA). 
Results 
Patient and tumor characteristics 
In the group of cases treated with both IO and brain RT, 36 patients were identified; 25 (69%) of them were men. 
Median age was 59 (range: 38-78). Seventeen patients were diagnosed with superficial spreading melanoma, 6 with 
nodular melanoma; histological classification was unknown in the remaining cases. Most patients (75%) had primary 
skin melanoma, 11% uveal melanoma, 3% mucosal melanoma. The majority of patients had distant visceral disease 
at the time of relapse (64%); the remaining ones had soft tissue metastases (skin in 14% of cases, lymph nodes with 
or without skin lesions in 22% of cases). Sites of distant disease were lung (n=10), bone (n=3), brain and other 
viscera (n=8 each). Baseline lactate dehydrogenase (LDH) serum level was higher than upper reference value in 4 
cases (11%) at diagnosis of metastatic disease. BRAF gene was mutated in 9 patients, mostly V600E (8 cases); in the 
remaining 75% of patients, BRAF was wild type. Corresponding characteristics of the control group of patients are 
reported in Supplementary table 1. 
Previous treatment characteristics 
A total of 58% of patients received surgery at one or more metastatic sites, which consisted in skin/soft tissue lesions 
(10 cases), loco-regional lymph nodes (6 cases), lung nodules (3 cases), gallbladder lesions (2 cases) and brain 
metastases (2 cases). All patients received first line therapy, which consisted in IO in 22 cases (anti-CTLA4 in 18, 
antiPD1 in 4), BRAF inhibitor with/without MEK inhibitor in 6 patients, and chemotherapy in 7 patients. The most 
frequent reason for first line discontinuation was disease progression (53% of cases). Best response to first line 
therapy was complete response in 2 patients, partial response in 11 patients, stable disease in 6 patients, progressive 
disease in 13 patients; response was not evaluable in 4 cases. Median PFS of first line treatment was 4 months, 
median OS 7 months. Twenty-six patients were treated with second line therapy, consisting mostly in an anti-CTLA4 
agent (50% of cases), followed by an anti-PD1 agent (35% of cases) and chemotherapy (15% of cases). Due to the 
high prevalence of ipilimumab administration in second line, most cases underwent regular conclusion of treatment 
(50%); in 19% of the remaining cases, treatment was interrupted for disease progression. No cases of complete 
response were seen in second line, but 4 patients obtained a partial response; the most frequently observed best 
response was progression (54% of cases). Median PFS and OS in second line were 2 and 4 months, respectively. 
Only 7 patients received a third line treatment for metastatic disease, consisting in an anti-PD1 agent in 4 cases, in an 
anti-CTLA4 one in 1 case, in cytotoxic chemotherapy in 2 cases. One patient obtained a brief disease stability, 
 
 
whereas the remaining ones underwent rapid progression (2 patients) or died before the first radiologic evaluation (4 
patients). Consequently, PFS and OS data were not evaluable in this setting. No significant differences in PFS could 
be observed stratifying patients for either treatment lines (p=.467), or specific ICI administered (p=.586). Similar 
results were observed for OS (p=.365 according to treatment line; p=.888 according to ICI received). Globally, the 
patients treated with brain RT and IO showed a tendency towards a worse outcome than controls treated with IO 
alone, without statistically significant differences in first line (p=.343 for PFS, p=0694 for OS) and a with worse PFS 
in second line (p=.027 for PFS, p=.933 for OS). Survival analyses according to treatment variables are detailed in 
Table 1 for the group of cases, in Supplementary table 1 for the group of controls.  
Brain progression and specific treatments 
Among cases, median interval from diagnosis to brain progression was 25 months (range: 5-180 months). Most 
patients presented multifocal brain disease (75% of cases) and all had concomitant extra-cranial localizations at the 
time of brain progression (skin and soft tissues in 25 cases, lung in 18 cases, bone in 3 cases, other viscera in 17 
cases). Brain disease was symptomatic in almost half of the patients (47%); 10 of them required an anti-epileptic 
therapy, 27 of them required steroids. Symptomatic patients had a significantly shorter PFS than asymptomatic ones 
(p=.049), without differences in OS (p=.266). The administration of steroids and anti-epileptics did not determine 
differences in PFS (p=.345 and .386, respectively) or OS (p=.815 and .254, respectively). All patients were treated 
with RT, either SBRT (50%) or WBRT (50%). RT was administered within 6 months since the beginning of 
ipilimumab in 23 patients, within 6 months since the beginning of nivolumab/pembrolizumab in the remaining 13 
patients. Median time between the diagnosis of CNS metastases and the beginning of RT was 5 weeks (range: 1-10 
weeks). In patients receiving SBRT, median radiation dose was 24 Gy (range: 18-25 Gy) in single fraction. Out of the 
18 patients receiving WBRT, 6 (33%) did not complete the treatment plan due to intracranial complications. Thus, 
only 12 subjects received a total of 30 Gy in 10 fractions. Intra-cranial disease response was not evaluable in 20 
patients, due to rapid clinical deterioration or death before the first radiologic evaluation. Among the remaining cases, 
brain response was mostly progression (11 cases), with a small number of stabilizations (3 cases) and partial 
responses (2 cases). Median time from RT to intra-cranial progression was 14 weeks (range: 5-56 weeks). Only a few 
patients could receive subsequent brain local therapies, consisting in either further RT (3 cases), or surgery (2 cases, 
as a consequence of acute complications). Four cases of neurologic toxicity potentially related to RT (including 
bleeding and epilepsy) were reported. No apparent exacerbation of IO toxicity due to RT was observed, as no cases of 
grade ≥3 adverse events occurred during concomitant/sequential administrations of such treatments. 
Fourteen patients (39%) presented extra-cranial progression after brain RT, with a median time to progression of 8 
weeks. The most common sites were lymph nodes and lungs (9 patients each), followed by other viscera (6 patients), 
skin (5 patients) and bone (3 patients). No differences in PFS were observed among patients with intra- and extra-
cranial progression after RT (p=.121). After a median follow-up of 2 months (range: 0-18 months) from RT, 9 
patients were alive and under treatment, 20 were dead, 7 were lost at follow-up. Median OS from RT was 6 months, 
without difference among cases treated with SBRT and WBRT (median OS 7 and 5 months, respectively; p=.1455).  
Discussion 
During the last years, significant efforts have been spent to ameliorate prognosis of patients with MM and encephalic 
disease [15]. RT is almost always needed to palliate neurologic symptoms and to obtain intra-cranial disease control, 
due to the scarce penetration of ICIs across the blood-brain barrier [16]. RT has a strong cytotoxic effect, mediated by 
the generation of oxygen free radicals capable to damage cancer DNA and proteins. It is likely that cell lysis leads to 
release of cancer antigens, increasing their presentation to immune cells and activating a specific anti-tumor response. 
On such a speculative basis, it was hypothesized that RT and IO could have a synergistic effect, with an increase of 
drug efficacy as a consequence of local RT [17, 18]. A consistent amount of pre-clinical data supports the hypothesis 
of an abscopal effect due to concomitant administration of IO and RT [7,8]. Nonetheless, clinical experiences 
provided more contradictory data, with some retrospective case series documenting a synergism between RT and IO, 
and others showing absence of benefit from combined treatments [19]. For example, Silk et al. reported a significant 
OS prolongation in patients with MM treated with SBRT and ipilimumab, in comparison with control cases receiving 
RT alone (19.9 versus 4.0 months, p=.009). Apparently no effects were seen with  WBRT in the same setting [8]. On 
the other hand, Patel et al. failed to document any differences in PFS and OS in a similar case series of melanoma 
 
 
patients treated with ipilimumab and brain RT, though in absence of toxicity concerns [9]. Recent data about anti-
PD1 agents in concomitance with RT are more encouraging [20-22]. For example, Choong et al. reported a promising 
OS of 20.4 months with SBRT administered within  6 weeks from an anti-PD1. The result was more unsatisfactory 
with anti-CTLA4 (median OS 7.5 months). Gaudy-Marqueste et al. evaluated a cohort of patients with metastatic 
melanoma treated with targeted drugs, anti-PD1 agents or chemotherapy in concomitance with SBRT, finding a 
particularly strong synergy with the combination of anti-PD1 and RT (median OS 14.8 months). As prospective data 
are lacking, the issue of identifying any synergy between RT and systemic treatments for MM remains unsolved. In 
this retrospective analysis, we could not find evidences of benefit for combined brain RT and IO. Indeed, no 
differences in outcome were observed in either the global population, or specific subgroups stratified for treatment 
line, ICI administered, RT technique, and intra/extra-cranial disease extent. The only significant observation 
concerned the presence of neurologic symptoms at brain relapse, which were related to a shorter PFS without 
differences in OS. Globally, patients outcome was poor, with most cases undergoing progression at first evaluation 
after RT, and a particularly short OS of only 6 months from brain local treatments. Notably, also extra-cranial disease 
showed a tendency towards rapid progression and no cases of abscopal effects were seen. Neither immune-mediated 
toxicity nor neurologic adverse events seemed to be worsened by the concomitance of the two approaches. The scant 
outcome of these patients was confirmed by the comparison with a control group treated with IO but not brain RT, 
showing a tendency towards worse PFS and OS for the patients receiving the combination of IO and RT. It has to be 
underlined that the control patients differed from the cases in the lower prevalence of brain disease and this point 
itself can explain their better prognosis. Nonetheless, such a comparison underlines the conclusion that in our case 
series the concomitant effect of IO and RT does not overcome the negative prognostic impact of brain disease itself. 
Different hypotheses can be proposed to explained the negative result of the analysis. First of all, the frequent 
administration of steroids to patients with intracranial disease, forced by the high prevalence of neurologic symptoms, 
might have weakened their immune response thus hiding a potential synergistic effect of IO. Notably, no evidence of 
synergy could be observed even in patients not receiving steroids, although the small number of these cases limits the 
possibility to draw inferences about this point. Secondarily, two thirds of the patients presented multifocal brain 
disease. In comparison with the situation of a solitary encephalic nodule or a small number of brain metastases, such 
a disease extension is generally associated to a poor prognosis and a limited benefit from RT. The similar outcome of 
patients with intra- and extra-cranial progression suggests an adjunctive consideration. It may be argued that 
encephalic progression entails a worse prognosis than systemic one. The absence of this difference in our case series 
may suggest that our patients presented a large burden of systemic disease in adjunct to brain metastases. Indeed, the 
vast majority of them had visceral metastases (lung, liver, or both), and only a minority developed brain progression 
in presence of soft tissue disease alone. The concomitance of brain lesions and a high burden of extra-cranial disease 
suggests that our population may have a particularly unfavorable prognosis, so that even the best combination of 
treatments might not induce a benefit. Another key point that could help to interpret the results is the fact that half of 
our patients (18 subjects) received SBRT. Some preclinical models have shown that abscopal effect is usually not 
observed after single fraction of RT, but only with fractionation [25]. This could be explained by the fact that a 
repeated radiation-induced cell damage could lead to a more effective tumor antigen presentation to immune cells. 
The limited number of our patients that completed the WBRT (12 cases) might help to interpret the negativity of our 
results. At the end, the long time interval between RT and IO (6 months) was chosen in order to include a higher 
number of patients in the analysis and was in line with previous works [9]. Although the prolonged effect of IO on 
immune response and the possibility to obtain disease control also after the conclusion of treatment support this 
rationale, such a wide time range between systemic and local therapy may have interfered with the results. However, 
it has to be underlined that most of the patients (70%) received RT within 3 months from the beginning of IO and 
33% of them received RT within the 4 weeks before the beginning of IO. Therefore, a radical change of the results 
excluding the cases with the longest time span is unlikely. The present study has some limitations that have to be 
evidenced. It reports the results of a small single Institution experience, with a limited number of cases. The 
retrospective collection of cases and controls led to unavoidable imbalance in the proportion of patients with brain 
disease, with potentially confounding effects on prognosis. Medical treatment was not homogeneous, as some 
patients received chemotherapy, some other IO with either ipilimumab or nivolumab or pembrolizumab. ICIs were 
 
 
administered in different treatment lines, with likely confounding effects on OS. RT was started at quite different 
times from IO (in concomitance, before or after treatment, with various length of drug interruption during local 
radiation therapy). At the end, the wide time span of the cases enrolled (from 2012 to 2016) led to lack of 
homogeneity between available treatments, which are not completely in line with current practice (e.g. high 
prevalence of ipilimumab and WBRT over anti-PD1 agents and SBRT, respectively). This could be of particular 
concern in consideration of the most recent data showing favorable outcome with the combination of anti-PD1 and 
SBRT, but quite worse results with anti-CTLA4 [22-24]. With all these limitations, the present study seems to 
evidence absence of synergy between brain RT and ICIs in MM. Given the limited and contrasting data present in 
literature, this issue remains open and prospective data are needed to gain definitive evidence about it. Indeed, the 
increasing treatment options for MM, including newer strategies of IO (e.g. combinations of anti-CTLA4 and anti-
PD1, novel drugs as anti-LAG3 and anti-TIM3, etc.), require urgent clarification of interactions with RT, whose 
effect may be crucial to impact on the outcome of patients with brain disease.  
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